journal article·2018-12Open access

Developing a Bright NIR‐II Fluorophore with Fast Renal Excretion and Its Application in Molecular Imaging of Immune Checkpoint PD‐L1

Hao Wan, Huilong Ma, Shoujun Zhu, FeiFei Wang, Ye Tian, Rui Ma, Qinglai Yang, Zhubin Hu, Tong Zhu, Weizhi Wang, Zhuoran Ma, Mingxi Zhang, Yeteng Zhong, Haitao Sun, Yongye Liang, Hongjie Dai

Advanced Functional Materials· Volume 28· Issue 50

Abstract

Abstract Fluorescence imaging in the second near‐infrared (NIR‐II) window holds impressive advantages of enhanced penetration depth and improved signal‐to‐noise ratio. Bright NIR‐II fluorophores with renal excretion ability and low tissue accumulation are favorable for in vivo molecular imaging applications as they can render the target‐mediated molecular imaging process easily distinguishable. Here, a probe (anti‐PD‐L1‐BGP6) comprising a fluorophore (IR‐BGP6) covalently bonded to the programmed cell death ligand‐1 monoclonal antibody (PD‐L1 mAb) for molecular imaging of immune checkpoint PD‐L1 (a targeting site upregulated in various tumors for cancer imaging) in the NIR‐II window is reported. Through molecular optimization, the bright NIR‐II fluorophore IR‐BGP6 with fast renal excretion (≈91% excretion in general through urine within the first 10 h postinjection) is developed. The conjugate anti‐PD‐L1‐BGP6 succeeds in profiling PD‐L1 expression and realizes efficient noninvasive molecular imaging in vivo, achieving a tumor to normal tissue (T/NT) signal ratio as high as ≈9.5. Compared with the NIR‐II fluorophore with high nonspecific tissue accumulation, IR‐BGP6 derived PD‐L1 imaging significantly enhances the molecular imaging performance, serving as a strong tool for potentially studying underlying mechanism of immunotherapy. The work provides rationales to design renal‐excreted NIR‐II fluorophores and illustrate their advantages for in vivo molecular imaging.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Cancer Immunotherapy and Biomarkers · Bladder and Urothelial Cancer Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry Stanford University Stanford CA 94305 USA

Department of Materials Science and Engineering South University of Science and Technology of China Shenzhen 518055 China

State Key Laboratory of Precision Spectroscopy School of Physics and Materials Science East China Normal University Shanghai 200062 China

School of Chemistry and Molecular Engineering East China Normal University Shanghai 200062 China

Collaborative Innovation Center of Extreme Optics Shanxi University Taiyuan Shanxi 030006 P. R. China

Funding

National Natural Science Foundation of China · National Institutes of Health

References (40)

Show source-provided references
1. Dai L. · Adv. Funct. Mater. · 2018 · 28 · 1077249
2. 10.1002/adfm.20160436610.1002/adfm.201604366 ↗
3. Bose C. K. · Contemp. Oncol. · 2017 · 21 · 189
4. 10.1212/WNL.000000000000436910.1212/WNL.0000000000004369 ↗
5. 10.1038/nrc323910.1038/nrc3239 ↗
6. 10.1002/adma.20170711210.1002/adma.201707112 ↗
7. Li K. · J. Drug Target. · 2018 · 1 · 1
8. b)X.Zhu J.Lang 2017 28 e64.10.1097/EDE.0000000000000702 ↗
9. 10.1038/ni.270310.1038/ni.2703 ↗
10. 10.1016/j.critrevonc.2017.06.00110.1016/j.critrevonc.2017.06.001 ↗
11. 10.18632/oncotarget.714310.18632/oncotarget.7143 ↗
12. 10.4161/21645515.2014.98340910.4161/21645515.2014.983409 ↗
13. 10.1093/intimm/dxu09510.1093/intimm/dxu095 ↗
14. 10.1177/153601211771845910.1177/1536012117718459 ↗
15. 10.1038/s41598-017-01000-210.1038/s41598-017-01000-2 ↗
16. 10.1186/s40425-016-0178-110.1186/s40425-016-0178-1 ↗
17. 10.1038/s41551-016-001010.1038/s41551-016-0010 ↗
18. 10.1002/adma.20170685610.1002/adma.201706856 ↗
19. 10.1039/C7SC00251C10.1039/C7SC00251C ↗
20. 10.1002/adma.20160549710.1002/adma.201605497 ↗
21. 10.1073/pnas.161799011410.1073/pnas.1617990114 ↗
22. 10.1021/jacs.7b1033410.1021/jacs.7b10334 ↗
23. 10.1038/ncomms520610.1038/ncomms5206 ↗
24. 10.1038/s41467-018-03505-410.1038/s41467-018-03505-4 ↗
25. 10.1002/anie.20150747310.1002/anie.201507473 ↗
26. 10.1038/nnano.2009.29410.1038/nnano.2009.294 ↗
27. 10.1038/s41551-017-005610.1038/s41551-017-0056 ↗
28. 10.1002/anie.20120605910.1002/anie.201206059 ↗
29. a)L.Liu S.Wang B.Zhao P.Pei Y.Fan X.Li F.Zhang 2018 57 7518;10.1002/anie.201802889 ↗
30. 10.1038/s41467-017-00917-610.1038/s41467-017-00917-6 ↗
31. 10.1038/nbt134010.1038/nbt1340 ↗
32. 10.1016/j.cbpa.2009.09.02910.1016/j.cbpa.2009.09.029 ↗
33. 10.1038/nrc88210.1038/nrc882 ↗
34. 10.1038/nmat447610.1038/nmat4476 ↗
35. 10.1002/adma.20160070610.1002/adma.201600706 ↗
36. 10.1021/acs.bioconjchem.7b0063110.1021/acs.bioconjchem.7b00631 ↗
37. 10.1016/j.ccell.2016.02.00410.1016/j.ccell.2016.02.004 ↗
38. 10.1038/mtm.2014.5810.1038/mtm.2014.58 ↗
39. 10.1016/S0005-2736(03)00114-710.1016/S0005-2736(03)00114-7 ↗
40. 10.1093/glycob/10.12.134710.1093/glycob/10.12.1347 ↗